Subscribe to the World's Most Popular ME-CFS Newsletter (it's free!)
Researchers studied the effect of selegiline, a specific monoamine oxidase B receptor inhibitor, against a placebo in 25 CFS patients over a six-week trial period. Patients filled out questionnaires about mood, fatigue, functional status and symptom severity at the beginning of the trial, after two weeks of treatment, and at the end of the trial. They found that the patients who took selegiline reported significant improvement in tension/anxiety, vigor and sexual relations, and that the drug was not acting as an antidepressant.
Natelson, B.H., et. al. (1998). Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome. Neuropsychobiology, 37:3, pp. 150–154.